Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hanna Shalev is active.

Publication


Featured researches published by Hanna Shalev.


Nature Genetics | 2002

Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia

Roxanne Y. Walder; Daniel Landau; Peter Meyer; Hanna Shalev; Maria Tsolia; Zvi Borochowitz; Melanie Barbara Boettger; Gretel Beck; Richard K. Englehardt; Rivka Carmi; Val C. Sheffield

Familial hypomagnesemia with secondary hypocalcemia (OMIM 602014) is an autosomal recessive disease that results in electrolyte abnormalities shortly after birth. Affected individuals show severe hypomagnesemia and hypocalcemia, which lead to seizures and tetany. The disorder has been thought to be caused by a defect in the intestinal absorption of magnesium, rather than by abnormal renal loss of magnesium. Restoring the concentrations of serum magnesium to normal values by high-dose magnesium supplementation can overcome the apparent defect in magnesium absorption and in serum concentrations of calcium. Life-long magnesium supplementation is required to overcome the defect in magnesium handling by these individuals. We previously mapped the gene locus to chromosome 9q in three large inbred kindreds from Israel. Here we report that mutation of TRPM6 causes hypomagnesemia with secondary hypocalcemia and show that individuals carrying mutations in this gene have abnormal renal magnesium excretion.


American Journal of Human Genetics | 1999

Complement Factor H Gene Mutation Associated with Autosomal Recessive Atypical Hemolytic Uremic Syndrome

Lihua Ying; Yitzhak Katz; Menachem Schlesinger; Rivka Carmi; Hanna Shalev; Neena B. Haider; Gretel Beck; Val C. Sheffield; Daniel Landau

Atypical hemolytic uremic syndrome (HUS) presents with the clinical features of hypertension, microangiopathic hemolytic anemia, and acute renal failure. Both dominant and recessive modes of inheritance have been reported. This study describes the genetic and functional analysis of a large Bedouin kindred with autosomal recessive HUS. The kindred consists of several related nuclear families in which all parent unions of affected children are consanguineous. A previous report demonstrated that a dominant form of HUS maps to chromosome 1q and that complement factor H (CFH), a regulatory component of the complement system, lies within the region and is involved in the dominant disorder. Early-onset and persistent hypocomplementemia in this Bedouin kindred prompted us to evaluate the CFH gene. Linkage analysis was performed, demonstrating linkage between the disorder and the markers near the CFH gene. Mutation analysis of the CFH coding region revealed a single missense mutation. Functional analyses demonstrate that the mutant CFH is properly expressed and synthesized but that it is not transported normally from the cell. This is the first study reporting that a recessive, atypical, early-onset, and relapsing HUS is associated with the CFH protein and that a CFH mutation affects intracellular trafficking and secretion.


Blood | 2008

Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I

Hannah Tamary; Hanna Shalev; Galit Perez-Avraham; Meira Zoldan; Itai Levi; Dorine W. Swinkels; Toshihiko Tanno; Jeffery L. Miller

Congenital dyserythropoietic anemia (CDA) is a rare group of red blood cell disorders characterized by ineffective erythropoiesis and increased iron absorption. To determine whether growth differentation factor 15 (GDF15) hyper-expression is associated with the ineffective erythropoiesis and iron-loading complications of CDA type I (CDA I), GDF15 levels and other markers of erythropoiesis and iron overload were studied in blood from 17 CDA I patients. Significantly higher levels of GDF15 were detected among the CDA I patients (10 239 +/- 3049 pg/mL) compared with healthy volunteers (269 +/- 238 pg/mL). In addition, GDF15 correlated significantly with several erythropoietic and iron parameters including Hepcidin-25, Ferritin, and Hepcidin-25/Ferritin ratios. These novel results suggest that CDA I patients express very high levels of serum GDF15, and that GDF15 contributes to the inappropriate suppression of hepcidin with subsequent secondary hemochromatosis.


European Journal of Human Genetics | 2003

CATSPER2, a human autosomal nonsyndromic male infertility gene.

Nili Avidan; Hannah Tamary; Orly Dgany; Daniel Cattan; Alexandre Pariente; Michel Thulliez; Nicolas Borot; Lucien Moati; Alain Barthelme; Lea Shalmon; Tatyana Krasnov; Edna Ben-Asher; Tsvyia Olender; Miriam Khen; Issac Yaniv; Rina Zaizov; Hanna Shalev; Jean Delaunay; Marc Fellous; Doron Lancet; Jacques S. Beckmann

In the course of positional cloning of the Congenital Dyserythropoietic Anemia type I (CDAI) [MIM 224120] gene on 15q15.1–15.3, we examined a family of French origin, in which the propositus suffered from asthenoteratozoospermia and nonsyndromic deafness in addition to CDAI. Two of his brothers had a similar phenotype. All three siblings were homozygous carriers of the CDA1 mutation as well as of a distally located ∼70 kb deletion of the proximal copy of a 106 kb tandem repeat on chromosome 15q15. These repeats encode four genes whose distal copies may be considered pseudogenes. Lack of functional stereocilin and CATSPER2 (a voltage-gate cation channel expressed specifically in spermatozoa) may explain the observed deafness and male infertility phenotypes. To the best of our knowledge, the involvement of CATSPER2 in asthenoteratozoospermia is the first description of a human autosomal gene defect associated with nonsyndromic male infertility.


American Journal of Human Genetics | 2002

Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1.

Orly Dgany; Nili Avidan; Jean Delaunay; Tatyana Krasnov; Lea Shalmon; Hanna Shalev; Tal Eidelitz‐Markus; Joseph Kapelushnik; Daniel Cattan; Alexandre Pariente; Michel Tulliez; Aurore Crétien; Pierre-Olivier Schischmanoff; Achille Iolascon; Eithan Fibach; Ariel Koren; Jochen Rössler; Martine Le Merrer; Isaac Yaniv; Rina Zaizov; Edna Ben-Asher; Tsvyia Olender; Doron Lancet; Jacques S. Beckmann; Hannah Tamary

Congenital dyserythropoietic anemias (CDAs) constitute a rare group of inherited red-blood-cell disorders associated with dysplastic changes in late erythroid precursors. CDA type I (CDAI [MIM 224120], gene symbol CDAN1) is characterized by erythroid pathological features such as internuclear chromatin bridges, spongy heterochromatin, and invagination of the nuclear membrane, carrying cytoplasmic organelles into the nucleus. A cluster of 45 highly inbred Israeli Bedouin with CDAI enabled the mapping of the CDAN1 disease gene to a 2-Mb interval, now refined to 1.2 Mb, containing 15 candidate genes on human chromosome 15q15 (Tamary et al. 1998). After the characterization and exclusion of 13 of these genes, we identified the CDAN1 gene through 12 different mutations in 9 families with CDAI. This 28-exon gene, which is transcribed ubiquitously into 4738 nt mRNA, was reconstructed on the basis of gene prediction and homology searches. It encodes codanin-1, a putative o-glycosylated protein of 1,226 amino acids, with no obvious transmembrane domains. Codanin-1 has a 150-residue amino-terminal domain with sequence similarity to collagens and two shorter segments that show weak similarities to the microtubule-associated proteins, MAP1B (neuraxin) and synapsin. These findings, and the cellular phenotype, suggest that codanin-1 may be involved in nuclear envelope integrity, conceivably related to microtubule attachments. The specific mechanisms by which codanin-1 underlies normal erythropoiesis remain to be elucidated.


Pediatric Nephrology | 1998

Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.

Melly Ohali; Hanna Shalev; Menachem Schlesinger; Yitzhak Katz; Leonid Kachko; Rivka Carmi; Shaul Sofer; Daniel Landau

Abstract. We describe the clinical course, complement components, and pathological findings of 10 infants with autosomal recessive hemolytic uremic syndrome (HUS). All patients were members of one extended highly inbred Bedouin kindred. The median age of presentation was 2 weeks (range 1–20 weeks). Eight patients died, 2 patients are alive, on dialysis. Renal biopsies revealed thrombotic microangiopathy with a predominant early arteriolar involvement and subsequent development of ischemic glomerular changes. Immunofluorescence was positive for C3 in glomeruli. All patients had low complement components levels during and between relapses, and in some this was evident soon after birth and prior to the onset of symptoms. This deficiency could not be normalized by repeated plasma transfusions. Biosynthetic labelling of patients’ fibroblasts demonstrated normal rates of C3 protein synthesis. Serum factor H levels were greatly decreased or absent in 4 patients tested and moderately decreased in 15 of 23 healthy unaffected siblings and patients. This defect may cause complement activation and consumption, possibly at the endothelial cell level.


Annals of Neurology | 2006

Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis

Lina Basel-Vanagaite; Liora Muncher; Rachel Straussberg; Metsada Pasmanik-Chor; Michal Yahav; Limor Rainshtein; Christopher A. Walsh; Nurit Magal; Ellen Taub; Valerie Drasinover; Hanna Shalev; Revital Attia; Gideon Rechavi; Amos J. Simon; Mordechai Shohat

The objective of this study was to identify the gene causing autosomal recessive infantile bilateral striatal necrosis.


Archives of Disease in Childhood | 1998

Clinical presentation and outcome in primary familial hypomagnesaemia

Hanna Shalev; Moshe Phillip; Aharon Galil; Rivka Carmi; Daniel Landau

The clinical presentation and long term outcome (mean follow up eight years, range 0.25 to 21) of 15 patients with autosomal recessive primary familial hypomagnesaemia is described. The most common (67%) presenting events were generalised hypocalcaemic-hypomagnesaemic seizures at a mean (SD) age of 4.9 (2.5) weeks. Thirteen infants, treated soon after diagnosis with high dose enteral magnesium developed normally. Their serum calcium returned to normal concentrations but serum magnesium could not be maintained at normal concentrations (0.53 (0.12 SD) mmol/l; normal >0.62). Delay in establishing a diagnosis led to a convulsive disorder with permanent neurological impairment in two infants. Reported complications of prolonged hypomagnesaemia such as renal stones, hypertension, arrhythmias, sudden death, or dyslipidaemia were not observed.


American Journal of Human Genetics | 1998

Localization of the Gene for Congenital Dyserythropoietic Anemia Type I to a <1-cM Interval on Chromosome 15q15.1-15.3

Hannah Tamary; Lea Shalmon; Hanna Shalev; Albudar Halil; Dina Dobrushin; Noga Ashkenazi; Meira Zoldan; Peretz Resnitzky; Michael Korostishevsky; Batsheva Bonne-Tamir; Rina Zaizov

Congenital dyserythropoietic anemias (CDA) are a rare group of red-blood-cell disorders of unknown etiology that are characterized by ineffective erythropoiesis, pathognomonic cytopathology of the nucleated red blood cells in the bone marrow, and secondary hemochromatosis. In CDA type I, bone-marrow electron microscopy reveals characteristic findings in erythroid precursors, including spongy heterochromatin and enlarged nuclear pores. Since the genetic basis of CDA type I is not evident, we used homozygosity and linkage mapping to localize the genetic defect responsible for CDA type I in 25 Bedouins from four large consanguineous families. We report the linkage of this disease to markers on chromosome 15 located at q15. 1-q15.3. Fourteen markers within a 12-cM interval were typed in the relevant family members. Nine of the markers yielded maximum LOD scores of 1.625-12.928 at a recombination fraction of .00. Linkage disequilibrium was found only with marker D15S779. Haplotype analysis revealed eight different carrier haplotypes and highlighted the existence of a founder haplotype. Identification of historical crossover events further narrowed the gene location to between D15S779 and D15S778. The data suggest localization of the CDA type I gene within a 0.5-cM interval. The founder mutation probably occurred >/= 400 years ago. Sequence analysis of the coding region of protein 4.2, the only known erythroid-specific gene in the locus, did not reveal any change in the CDA type I patients. Future analysis of this locus may lead to the identification of a gene essential to normal erythropoiesis.


The Journal of Pediatrics | 1997

Neonatal manifestations of congenital dyserythropoietic anemia type I

Hanna Shalev; Hannah Tamary; Dina Shaft; Peretz Reznitsky; Rina Zaizov

Congenital dyserythropoietic anemia type I is a rare inherited bone marrow disorder characterised by macrocytic anemia with pathognomonic morphological ultrastructural features in erythroid precursors. The disease is usually not diagnosed in the neonatal period. In a retrospective study of 31 patients we found that 17 were first seen in the neonatal age with significant anemia (birth hematocrit 0.34 +/- 0.07); 14 of the 17 infants also had early jaundice. Six infants were small for gestational age and two had syndactyly. Although rare, congenital dyserythropoietic anemia type I should be considered in the differential diagnosis of neonatal anemia.

Collaboration


Dive into the Hanna Shalev's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Landau

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Joseph Kapelushnik

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rivka Carmi

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Asher Moser

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar

Itai Levi

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge